Charles R Crain
Overview
Explore the profile of Charles R Crain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wohlwend J, Nathan A, Shalon N, Crain C, Tano-Menka R, Goldberg B, et al.
Nat Mach Intell
. 2025 Feb;
7(2):232-243.
PMID: 40008296
Accurate in silico determination of CD8 T cell epitopes would greatly enhance T cell-based vaccine development, but current prediction models are not reliably successful. Here, motivated by recent successes applying...
2.
Tano-Menka R, Singh N, Muzhingi I, Li X, Mandanas M, Kaseke C, et al.
Structure
. 2024 May;
32(8):1121-1136.e5.
PMID: 38733995
Immunogenetic studies have shown that specific HLA-B residues (67, 70, 97, and 156) mediate the impact of HLA class I on HIV infection, but the molecular basis is not well...
3.
Choudhary M, Deo R, Evering T, Chew K, Giganti M, Moser C, et al.
J Infect Dis
. 2024 May;
230(2):394-402.
PMID: 38716969
Background: Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether combination mAbs offer a benefit over single-active...
4.
Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell G, Sharaf R, et al.
Nat Med
. 2023 Nov;
29(12):3212-3223.
PMID: 37957382
Non-suppressible HIV-1 viremia (NSV) is defined as persistent low-level viremia on antiretroviral therapy (ART) without evidence of ART non-adherence or significant drug resistance. Unraveling the mechanisms behind NSV would broaden...
5.
Bhattacharyya S, Crain C, Goldberg B, Gaiha G
Curr Opin HIV AIDS
. 2023 Aug;
18(5):257-263.
PMID: 37535040
Purpose Of Review: CD8+ T cell responses are a key component of the host immune response to human immunodeficiency virus (HIV) but vary significantly across individuals with distinct clinical outcomes....
6.
Choudhary M, Chew K, Deo R, Flynn J, Regan J, Crain C, et al.
Nat Microbiol
. 2022 Oct;
7(11):1906-1917.
PMID: 36289399
SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have been reported. However, it remains unclear whether in vivo emergence of SARS-CoV-2 resistance mutations alters viral replication dynamics or...
7.
Boucau J, Chew K, Choudhary M, Deo R, Regan J, Flynn J, et al.
Cell Rep Med
. 2022 Jul;
3(7):100678.
PMID: 35793677
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among the treatments recommended for high-risk ambulatory persons with coronavirus 2019 (COVID-19). Here, we study viral culture dynamics post-treatment...
8.
Boucau J, Chew K, Choudhary M, Deo R, Regan J, Flynn J, et al.
medRxiv
. 2022 Jan;
PMID: 35018382
Monoclonal antibodies (mAbs) are the treatment of choice for high-risk ambulatory persons with mild to moderate COVID-19. We studied viral culture dynamics post-treatment in a subset of participants receiving the...
9.
Choudhary M, Chew K, Deo R, Flynn J, Regan J, Crain C, et al.
medRxiv
. 2021 Sep;
PMID: 34545376
Resistance mutations to monoclonal antibody (mAb) therapy has been reported, but in the non-immunosuppressed population, it is unclear if emergence of SARS-CoV-2 resistance mutations alters either viral replication dynamics or...
10.
Choudhary M, Crain C, Qiu X, Hanage W, Li J
Clin Infect Dis
. 2021 Apr;
74(2):237-245.
PMID: 33906227
Background: Both severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection and persistent infection have been reported, but sequence characteristics in these scenarios have not been described. We assessed published cases...